Inquiry Basket
Loading ......
Antibody drug potency describes the ability of a therapeutic antibody to elicit specific and measurable biological effects and it recognized as a critical quality attribute (CQA). As antibody therapeutics diversify - from conventional monoclonal antibodies to Fc-engineered antibodies and antibody–drug conjugates (ADCs) - reliable potency assessment has become increasingly important across drug development and manufacturing. Rather than simple concentration-based measurements, antibody potency is determined by functional pharmacodynamic (PD) responses, including target engagement and downstream cellular effects.
Because antibody drugs act through highly specific interactions at the level of individual immune or tumor cells, flow cytometry provides a uniquely powerful platform for single-cell–resolved potency evaluation.
Receptor occupancy (RO) is a critical indicator of antibody pharmacology and potency, especially for antagonistic or blocking antibodies. Flow cytometry allows direct measurement of:
Fig. 1 The three basic RO assay formats
Because RO assays are highly MoA-aligned, they are frequently used to support PK/PD relationships, bridge nonclinical and clinical data, and provide mechanistic justification for potency specifications.
Many therapeutic antibodies exert their effects by activating or inhibiting intracellular signaling pathways. Phospho-flow cytometry enables sensitive, quantitative detection of pathway-specific phosphorylation events at the single-cell level. Common applications include:
Compared with bulk methods such as Western blotting, phospho-flow offers superior throughput, quantitative robustness, and the ability to resolve signaling responses within defined cell subsets—making it a powerful potency tool for signaling-driven antibodies.
For antibodies designed to recruit immune effector functions, functional assays are often required to demonstrate true biological potency. Flow cytometry excels in this area by enabling multiparametric evaluation of both target and effector cells.
Fig. 2 Schematic representation of the mechanisms of action used by naked antibodies to inhibit tumor growth.
Antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are critical Fc-mediated effector mechanisms that directly contribute to the clinical efficacy of many therapeutic antibodies, particularly in oncology and immunology. For antibodies designed to engage Fcγ receptors on immune effector cells, functional activity—not binding alone—defines true potency.
Flow cytometry–based ADCC and ADCP assays enable multiparametric, single-cell analysis of both effector and target populations within the same assay, providing a biologically faithful representation of Fc functionality. Flow cytometry can quantitatively assess:
Complement-dependent cytotoxicity (CDC) represents another important Fc-driven mechanism for a subset of therapeutic antibodies. Accurate assessment of CDC requires detection of both cellular outcomes and complement activation events, which are challenging to capture with traditional bulk lysis methods.
Flow cytometry–based CDC assays provide a robust and flexible alternative by enabling direct, cell-specific measurements, including:
For ADCs, internalization efficiency is a prerequisite for payload delivery and therapeutic efficacy. Flow cytometry enables quantitative analysis of antibody internalization using pH-sensitive dyes or surface-stripping approaches. While internalization assays are not typically used as release potency tests, they provide critical mechanistic support during ADC optimization and candidate selection.
As antibody drugs become more sophisticated, potency assessment must move beyond simplified binding measurements toward biologically meaningful, mechanism-driven assays. Flow cytometry uniquely addresses this need by integrating binding, signaling, and functional readouts at the single-cell level.
Whether used for routine lot release, stability monitoring, or deep mechanistic characterization, flow cytometry has become an indispensable platform for antibody drug potency assessment, supporting robust development, regulatory compliance, and ultimately, consistent clinical performance.
Loading ......
